Attovia Therapeutics Q3 net loss widens 62% to $22.27 million
ATTO•Attovia Therapeutics’ third-quarter 2026 net loss widened 62% year over year to $22.27 million, while revenue fell to nil. Cash, cash equivalents and marketable securities totaled $395.94 million at September 30, with funding expected to last into 2030.
1. Quarterly results
Attovia Therapeutics’ third-quarter 2026 net loss widened 62% year over year to $22.27 million, and revenue fell to nil. Research and development expenses rose 65% to $20.29 million. The company reported $395.94 million in cash, cash equivalents and marketable securities at September 30, 2026, and said funding is expected to last into 2030.
2. ATTO-1310 update
ATTO-1310 delivered positive 12-week Phase 1b results in chronic pruritus and high-itch atopic dermatitis after a single dose. Two Phase 2 trials of the drug remain on track to begin in the first half of 2027.
